Biocytogen reports nine-month revenue growth of 49.09%
Regulatory / securities filing · 百奥赛图 / 巨潮资讯 CNinfo
Source published: · Event / reporting date: 2026-09-30
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
Why it may matter
The model and antibody-licensing platform merits attention, while milestone timing can affect quarter-to-quarter results and comparisons with service-focused peers.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections